57 studies found for:    "Carcinoid syndrome"
Show Display Options
RSS Create an RSS feed from your search for:
"Carcinoid syndrome"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Withdrawn Study of Panitumumab in the Treatment of Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention: Drug: Panitumumab
2 Completed Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome
Condition: Symptoms of Carcinoid Syndrome
Interventions: Drug: Low Dose LX1606 - Day 1 (start);   Drug: Mid-low dose LX1606 - Day 15 (start);   Drug: Mid-high dose LX1606 - Day 29 (start);   Drug: High dose LX1606 - Day 43 (start);   Drug: 4-Week Open Label Dose Extension;   Drug: 72-Week Open Label Dose Extension
3 Terminated Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
Condition: Malignant Carcinoid Syndrome
Interventions: Drug: lanreotide Autogel (somatostatin analogue);   Drug: Sandostatin long acting release (LAR) Depot (somatostatin analogue)
4 Completed Effects of Serotonin Excess on Bone in Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention:
5 Terminated Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention: Drug: Octreotide
6 Active, not recruiting An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Condition: Carcinoid Syndrome
Interventions: Drug: Somatuline Depot (lanreotide);   Drug: placebo
7 Terminated Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention: Drug: BIM 23A760
8 Recruiting Telotristat Etiprate for Carcinoid Syndrome Therapy
Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg);   Drug: Placebo
9 Recruiting TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg);   Drug: Placebo tablets
10 Completed A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
Condition: Neuroendocrine Tumour (NET) With Carcinoid Syndrome
Intervention:
11 Recruiting Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Condition: Carcinoid Syndrome
Intervention: Drug: Telotristat etiprate tablets (250 mg)
12 Completed Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
Condition: Carcinoid Syndrome
Interventions: Drug: Low Dose Part 1;   Drug: Mid-Low Dose Part 1;   Drug: Mid-High Dose Part 1;   Drug: High Dose Part 1;   Drug: Part 2 Expanded Cohort;   Drug: Placebo;   Drug: Open Label Dose Extension;   Drug: Open Label Extension 2;   Drug: Open Label Extension 3
13 Completed An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
Condition: Carcinoid Syndrome
Intervention: Drug: 500 mg [14C]-LX1606
14 Active, not recruiting
Has Results
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Conditions: Carcinoid Tumor;   Malignant Carcinoid Syndrome
Interventions: Drug: Octreotide;   Drug: Placebo;   Drug: Everolimus
15 Recruiting P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
Condition: Neuroendocrine Carcinoma
Intervention: Drug: Octreotide LAR
16 Completed Azilect + Antidepressant Chart Review
Condition: Serotonin Syndrome
Interventions: Drug: Group R+AD Rasagiline + Antidepressant;   Drug: Group R Rasagiline;   Drug: Group AD Anti-PD + Antidepressant
17 Completed Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
Conditions: Metastatic Gastrointestinal Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Regional Gastrointestinal Carcinoid Tumor
Interventions: Biological: PEG-interferon alfa-2b;   Biological: bevacizumab;   Other: laboratory biomarker analysis
18 Completed Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction
Conditions: Colorectal Cancer;   Constipation, Impaction, and Bowel Obstruction;   Extrahepatic Bile Duct Cancer;   Gastric Cancer;   Gastrointestinal Carcinoid Tumor;   Gastrointestinal Stromal Tumor;   Pancreatic Cancer;   Quality of Life;   Small Intestine Cancer
Interventions: Procedure: bowel obstruction management;   Procedure: quality-of-life assessment
19 Completed Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction
Conditions: Colorectal Cancer;   Constipation, Impaction, and Bowel Obstruction;   Gastric Cancer;   Gastrointestinal Carcinoid Tumor;   Gastrointestinal Stromal Tumor;   Quality of Life;   Small Intestine Cancer
Interventions: Procedure: bowel obstruction management;   Procedure: quality-of-life assessment
20 Active, not recruiting Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Neuroendocrine Tumor;   Pancreatic Polypeptide Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma;   WDHA Syndrome
Intervention: Drug: sorafenib tosylate

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years